您要查找的是不是：
- platelet survival time 血小板存活时间
- The aver age survival time was 6 months. 平均生存时间为6个月。
- It can prolong mouse s survival time in hypoxia. 醒神液能延长小鼠耐缺氧存活时间。
- The median survival time for the entire sample was 34 months. 二年及五年的存活率各为65%25及25%25。
- The Prediction of the Survival Time about Hepatoma Patients with the BP Neural Network Method. BP神经网络预测肝癌患者生存期的研究。
- The overall response rate was 73.5% with a CR rate of 17.6% .Median survival time was 9.5 months. 治疗总有效率为73.;5%25，其中完全缓解率为17
- The average survival time was prolonged but the rate of death protection was lower than that of Virazole group. 但死亡保护率低于病毒唑。
- Survival time and complete remission duration(CRD) were evaluated using Kaplan-Meier method. Kaplan -Meier方法评价两组生存期和缓解期 ;
- In addition,the survival time was increased to 75%in CQ group and to 70% in DXM group. 此外，PLA2抑制剂可使家兔8h存活率由48%25提高到75%25（CQ组）和70%25（DXM组）。
- Asarinin could prolong the survival time of allografts,which was similar to CsA group(P>0.05). 移植心存活时间;CsA组、细辛脂素组和混合药物组均较阳性对照组显著延长(P<0.;01)。
- DRC treatment prolonged the survival time of mice and the duration of electrocardiograph in trachea closed mice. 实验结果表明：DRC能显著延长小鼠常压缺氧环境下的存活时间以及夹闭气管小鼠心电图消失时间；
- The survival time in BPI group was significantly higher than in physiological saline (PS) group. BPI治疗组动物存活时间明显长于生理盐水组 ;
- PAP increased, survival time is shorttcr and MDA content increased after L-NNA infusion. 注入L-NNA后显著增加了休克后PAP,缩短了存活时间,并使血中MDA含量明显增加。
- Tumor antigen specific CTLs may prevent metastasis in the LCI-D20 model and prolong the survival time. 肿瘤抗原特异性CTL可以预防LCI-D20模型肝癌发生转移,延长动物存活时间。
- Median survival time(MST)was 10 months. Median time to progression (MTTP) was 8 months. 中位生存时间(MST)为10个月,中位进展时间(MTTP)为8个月。
- The prognoses of these patients are extremely poor with a mean survival time of only 7.6 weeks. 这些病人的预后很差，平均存活时间只有7.;6周。
- The algorithm is applied to an example involving data for survival time for carcinoma of the oropharynx. 该算法应用于一个涉及口咽癌患者生存时间数据的例子。
- MSI-positive patients had significantly shorter survival time than MSI-negative ones had (P＝0.0001). MSI阳性患者的生存时间显著地低于MSI阴性患者(P＝0.;0001)。
- Onders, noting that axonal sprouting will likely afford patients the longest survival time. 神经轴分枝似乎可以提供与患者最长的存活期。
- IHC analysis showed survival time were shorter in the high ki-67 group than in the low group（P<0.05）. 临床资料单因素分析显示，临床分期、结外侵犯情况、ECOG评分、血清乳酸脱氢酶水平及疗效均为弥漫大B细胞淋巴瘤的独立预后因素（P<0.;05），是否合并放疗或使用美罗华对预后影响无统计学差别；
